多发性结直肠肝转移保实质单期肝切除的技术演变与结果
该前瞻性队列纳入2004—2023年407例≥4枚双叶结直肠肝转移患者,按意向治疗分析POSH的技术演变与长期结局。388例行POSH、17例行TSH;切除面积与肿瘤数目比由0.67降至0.41(P=0.024),207例POSH后不再需要TSH。R1v结局与R0相当,R1p的OS、RFS和局部复发更差。
要点
- POSH技术演进后切除面积与肿瘤数目比由0.67降至0.41,207例后不再行TSH。
- R1v(肿瘤-血管分离)结局与R0相当,支持血管分离的肿瘤学有效性。
- R1p(肿瘤-实质暴露)的OS、RFS和局部复发均更差,需重视切缘类型。
核心结论
- POSH对双叶结直肠肝转移有效,肿瘤聚簇技术进步使复杂病例也不再需要TSH。
- R1v结局与R0相当,证实血管分离的肿瘤学有效性。
研究设计与样本
- 前瞻性队列研究,纳入2004—2023年≥4枚双叶结直肠肝转移患者407例,按意向治疗分析。
- 388例行POSH,17例行TSH;POSH病例按手术切缘分类。
主要发现
- 切除面积与肿瘤数目比从2004—2007年的0.67改善至2020—2023年的0.41(P=0.024),207例POSH后不再行TSH。
- POSH病例中R0 105例(27.4%)、R1p 153例(39.9%)、R1v 37例(9.7%)、R1vp 88例(23.0%)。
- R1v结局与R0相当,R1p的OS、RFS和局部复发更差(P<0.05),R1vp结局居中。
- 肿瘤大小(HR 1.071,P=0.002)、原发肿瘤淋巴结状态(HR 1.695,P=0.005)和R1p切缘(HR 1.481,P=0.024)预测OS。
- 主要并发症发生率9.3%,90天死亡率0.8%;122例肝内复发中93例(76.2%)可行再次肝切除,5年OS获益显著。
关键数值与推荐
- R0 105例(27.4%)、R1p 153例(39.9%)、R1v 37例(9.7%)、R1vp 88例(23.0%)。
- 主要并发症9.3%,90天死亡率0.8%;再次肝切除可行93/122例(76.2%)。
- OS预测因素:肿瘤大小HR 1.071(P=0.002)、原发肿瘤淋巴结状态HR 1.695(P=0.005)、R1p切缘HR 1.481(P=0.024)。
临床怎么用
- 对多发性双叶结直肠肝转移可采用POSH,随着肿瘤聚簇技术成熟可避免TSH。
- R1v可作为可接受的切缘状态,R1p需更谨慎评估并加强随访。
- 肝内复发后再次肝切除可行比例较高(76.2%),应积极评估。
局限性
- 为单中心前瞻性队列,POSH与TSH分组非随机。
- 原文摘要未报告R1vp的具体风险比及随访时间等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Evaluate the technical development and long-term outcomes of Parenchymal-sparing One-Stage Hepatectomy (POSH) for colorectal liver metastases (CLM). SUMMARY BACKGROUND DATA: For multiple bilobar CLM, 2-stage hepatectomy (TSH) is suggested, with liver transplant proposed for unresectable cases. In this context, POSH showed effectiveness. METHODS: A prospective cohort of patients with ≥4 bilobar CLM (2004-2023) was analyzed using an intention-to-treat approach. POSH patients were classified by surgical margin. The primary endpoint was the technique evolution in terms of complexity, feasibility, and indications; secondary endpoints included POSH oncological validity, safety, and survival. RESULTS: Of 407 patients, 388 underwent POSH, and 17 TSH. Resection area-to-tumor number ratio improved from 0.67 (2004-2007) to 0.41 (2020-2023, P =0.024), eliminating TSH after 207 POSH cases. Among POSH cases: 105 (27.4%) were R0, 153 (39.9%) R1p (tumor-parenchymal exposure), 37 (9.7%) R1v (tumor-vessel detachment), and 88 (23.0%) R1vp (vascular/parenchymal exposure). R1v had outcomes comparable to R0, while R1p had worse OS, RFS, and local recurrence ( P <0.05). R1vp showed intermediate outcomes. Tumor size (HR 1.071, P =0.002), primary tumor nodal status (HR 1.695, P =0.005), and R1p margin (HR 1.481, P =0.024) predicted OS. Major complications occurred in 9.3%, 90-day mortality was 0.8%. Redo-hepatectomy was feasible in 93 of 122 (76.2%) patients with intrahepatic recurrence, providing a significant 5-year OS benefit. CONCLUSIONS: POSH is effective for bilobar CLM. Advancements in tumor clustering eliminated the need for TSH even in complex cases. R1v outcomes confirm the validity of vascular detachment.
引用
- Torzilli G, Milana F, Perano V, et al. From Cherry Picking to R1vasc, Clusters, and Compass Points: Evolution, Technique, and Results of Parenchymal-sparing One Stage Hepatectomy for Multiple Colorectal Liver Metastases. Ann Surg. 2025. PMID: 40778642. doi:10.1097/SLA.0000000000006891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。